Evidence map›Paper›PMID 35805023›Full record

ArticleCancers2022

Identifying Lethal Dependencies with HUGE Predictive Power.

Marian Gimeno, Edurne San José-Enériz, Angel Rubio, Leire Garate, Estíbaliz Miranda, Carlos Castilla, Xabier Agirre, Felipe Prosper, Fernando Carazo

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Marian GimenoDepartamento de Ingeniería Biomédica y Ciencias, TECNUN, Universidad de Navarra, 20009 San Sebastian, Spain.ORCID 0000-0002-0756-3055
Edurne San José-EnérizPrograma Hemato-Oncología, Centro de Investigación Médica Aplicada, IDISNA, Universidad de Navarra, 31008 Pamplona, Spain.
Angel RubioDepartamento de Ingeniería Biomédica y Ciencias, TECNUN, Universidad de Navarra, 20009 San Sebastian, Spain.
Leire GarateCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.
Estíbaliz MirandaPrograma Hemato-Oncología, Centro de Investigación Médica Aplicada, IDISNA, Universidad de Navarra, 31008 Pamplona, Spain.
Carlos CastillaDepartamento de Ingeniería Biomédica y Ciencias, TECNUN, Universidad de Navarra, 20009 San Sebastian, Spain.ORCID 0000-0002-6087-3140
Xabier AgirrePrograma Hemato-Oncología, Centro de Investigación Médica Aplicada, IDISNA, Universidad de Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-6558-9560
Felipe ProsperPrograma Hemato-Oncología, Centro de Investigación Médica Aplicada, IDISNA, Universidad de Navarra, 31008 Pamplona, Spain.ORCID 0000-0001-6115-8790
Fernando CarazoDepartamento de Ingeniería Biomédica y Ciencias, TECNUN, Universidad de Navarra, 20009 San Sebastian, Spain.ORCID 0000-0002-4288-3652
Universidad de Navarra · ESCentro de Investigación Biomédica en Red de Cáncer · ESClinica Universidad de Navarra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent functional genomic screens—such as CRISPR-Cas9 or RNAi screening—have fostered a new wave of targeted treatments based on the concept of synthetic lethality. These approaches identified LEthal Dependencies (LEDs) by estimating the effect of genetic events on cell viability. The multiple-hypothesis problem is related to a large number of gene knockouts limiting the statistical power of these studies. Here, we show that predictions of LEDs from functional screens can be dramatically improved by incorporating the “HUb effect in Genetic Essentiality” (HUGE) of gene alterations. We analyze three recent genome-wide loss-of-function screens—Project Score, CERES score and DEMETER score—identifying LEDs with 75 times larger statistical power than using state-of-the-art methods. Using acute myeloid leukemia, breast cancer, lung adenocarcinoma and colon adenocarcinoma as disease models, we validate that our predictions are enriched in a recent harmonized knowledge base of clinical interpretations of somatic genomic variants in cancer (AUROC > 0.87). Our approach is effective even in tumors with large genetic heterogeneity such as acute myeloid leukemia, where we identified LEDs not recalled by previous pipelines, including FLT3-mutant genotypes sensitive to FLT3 inhibitors. Interestingly, in-vitro validations confirm lethal dependencies of either NRAS or PTPN11 depending on the NRAS mutational status. HUGE will hopefully help discover novel genetic dependencies amenable for precision-targeted therapies in cancer. All the graphs showing lethal dependencies for the 19 tumor types analyzed can be visualized in an interactive tool.

Indexed as

CRISPR-Cas9 screeningprecision medicinesynthetic lethality

Identifiers

PMID35805023
PMCPMC9264916
OpenAlexW4283770508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.